Return to homepagePandemic Pact

Isolating and characterizing the human antibodies that neutralize SARS-CoV-2 (2019-NCOV THERAMAB project)

  • Funded by Institut Pasteur International Network (IPIN)
  • Total publications:0 publications

Grant number: 2019-NCOV THERAMAB

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Institut Pasteur International Network (IPIN)

  • Principal Investigator

    Pending

  • Research Location

    France

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Immunity

  • Special Interest Tags

    N/A

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Aim:to elucidate the mechanisms behind the antibody responses to SARS-CoV-2 and investigate the role they may play in eliminating the virus in infected individuals. The idea is to improve our understanding of the antibody responses of anti-SARS-CoV-2 memory B lymphocytes at molecular and functional level (B lymphocytes are the immune cells that produce antibodies). The memory B cells that develop after an initial infection have a long life span and are capable of intervening rapidly and effectively in the event of reinfection. The project aims to harness the discoveries made to develop a treatment based on the use of human neutralizing antibodies (immunotherapy).